GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » EV-to-EBIT

Sun Biomedical (ASX:SBN) EV-to-EBIT : -0.47 (As of Jun. 14, 2024)


View and export this data going back to . Start your Free Trial

What is Sun Biomedical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sun Biomedical's Enterprise Value is A$9.46 Mil. Sun Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.93 Mil. Therefore, Sun Biomedical's EV-to-EBIT for today is -0.47.

The historical rank and industry rank for Sun Biomedical's EV-to-EBIT or its related term are showing as below:

ASX:SBN' s EV-to-EBIT Range Over the Past 10 Years
Min: -15.58   Med: -0.25   Max: 2.15
Current: -15.19

During the past 13 years, the highest EV-to-EBIT of Sun Biomedical was 2.15. The lowest was -15.58. And the median was -0.25.

ASX:SBN's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.71 vs ASX:SBN: -15.19

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sun Biomedical's Enterprise Value for the quarter that ended in Dec. 2023 was A$0.00 Mil. Sun Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.93 Mil. Sun Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was %.


Sun Biomedical EV-to-EBIT Historical Data

The historical data trend for Sun Biomedical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical EV-to-EBIT Chart

Sun Biomedical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.29 -9.04 -3.52 -1.71 -0.97

Sun Biomedical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.71 - -0.97 -

Competitive Comparison of Sun Biomedical's EV-to-EBIT

For the Biotechnology subindustry, Sun Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sun Biomedical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sun Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sun Biomedical's EV-to-EBIT falls into.



Sun Biomedical EV-to-EBIT Calculation

Sun Biomedical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=9.458/-19.929
=-0.47

Sun Biomedical's current Enterprise Value is A$9.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sun Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Biomedical  (ASX:SBN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sun Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-19.929/0
= %

Sun Biomedical's Enterprise Value for the quarter that ended in Dec. 2023 was A$0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sun Biomedical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-19.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sun Biomedical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sun Biomedical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sun Biomedical (ASX:SBN) Business Description

Traded in Other Exchanges
Address
425 Smith Street, Fitzroy, VIC, AUS, 3065
Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines